Literature DB >> 1903355

The epidemiology of Neisseria gonorrhoeae isolates in Dakar, Sénégal 1982-1986: antimicrobial resistance, auxotypes and plasmid profiles.

I Lind1, M Arborio, M W Bentzon, Y Buisson, M Guibourdenche, K Reimann, J Y Riou.   

Abstract

A total of 460 Neisseria gonorrhoeae isolates from patients seen at three clinics in Dakar, Sénégal, 1982-1986, have been investigated. In this period a significant change in antimicrobial susceptibility was observed: the percentage of strains susceptible to penicillin (MIC less than or equal to 0.08 micrograms/ml) fell from 61 to 18 (p less than 0.0001) and the percentage of resistant strains (MIC greater than or equal to 1.2 micrograms/ml) increased from 18 to 46. Among penicillin-resistant strains the proportion of penicillinase-producing strains (PPNG) was fairly constant (range 35-55%). The determination of susceptibility to anti-microbial agents performed locally allowed detection of approximately all PPNG strains whereas the increase in the occurrence of strains with chromosomally determined resistance was not revealed. The study comprised 70 PPNG strains of which 19% (13/70) carried the 7.4 kb Asian plasmid and 81% (57/70) the 5.3 kb African plasmid. None of these strains possessed the 38 kb conjugative plasmid, whereas it was found in 4.5% of the 376 non-PPNG strains available for plasmid analysis; 92% (410/446) of all strains had the small 4.2 kb plasmid and 5.4% (24/446) did not contain any plasmid. Overall, auxotype zero and proline-requiring strains were predominant, accounting for 53% (244/460) and 28% (131/460), respectively. In general, PPNG strains carrying the 5.3 kb plasmid were auxotype zero (49/57 = 86%) and those carrying the 7.4 kb plasmid were proline-requiring (9/13 = 69%).

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1903355      PMCID: PMC1194642          DOI: 10.1136/sti.67.2.107

Source DB:  PubMed          Journal:  Genitourin Med        ISSN: 0266-4348


  19 in total

Review 1.  Management of antibiotic-resistant Neisseria gonorrhoeae.

Authors:  F N Judson
Journal:  Ann Intern Med       Date:  1989-01-01       Impact factor: 25.391

2.  Changing antibiotic susceptibility of Neisseria gonorrhoeae in Franceville, Gabon.

Authors:  M Peeters; E H Frost; M Collet; S Ossari; F Yvert; B Ivanoff
Journal:  Antimicrob Agents Chemother       Date:  1987-08       Impact factor: 5.191

3.  Nutritional profiles of Neisseria gonorrhoeae, Neisseria meningitidis, and Neisseria lactamica in chemically defined media and the use of growth requirements for gonococcal typing.

Authors:  B W Catlin
Journal:  J Infect Dis       Date:  1973-08       Impact factor: 5.226

4.  Antimicrobial susceptibility testing of Neisseria gonorrhoeae: a trial organised as part of the United Kingdom national external quality assessment scheme for microbiology.

Authors:  J J Snell; D F Brown
Journal:  J Clin Pathol       Date:  1988-01       Impact factor: 3.411

5.  Susceptibility testing of Neisseria gonorrhoeae to penicillin and spectinomycin in a diagnostic laboratory.

Authors:  M J Gill; C A Ison
Journal:  J Clin Pathol       Date:  1988-09       Impact factor: 3.411

6.  Rapid procedure for isolation of plasmid DNA and application to epidemiological analysis.

Authors:  S Takahashi; Y Nagano
Journal:  J Clin Microbiol       Date:  1984-10       Impact factor: 5.948

7.  Frequency in the United States of non-beta-lactamase-producing strains of Neisseria gonorrhoeae possessing the 24.5-Mdal conjugative plasmid.

Authors:  J S Knapp; J M Zenilman; R J Rice; M C Roberts; S A McIntire; S A Morse
Journal:  Sex Transm Dis       Date:  1989 Apr-Jun       Impact factor: 2.830

8.  Standardization of disk diffusion and agar dilution susceptibility tests for Neisseria gonorrhoeae: interpretive criteria and quality control guidelines for ceftriaxone, penicillin, spectinomycin, and tetracycline.

Authors:  R N Jones; T L Gavan; C Thornsberry; P C Fuchs; E H Gerlach; J S Knapp; P Murray; J A Washington
Journal:  J Clin Microbiol       Date:  1989-12       Impact factor: 5.948

9.  In-vitro susceptibility of Neisseria gonorrhoeae to thiamphenicol: results for selected groups of strains from different geographic areas and from different times.

Authors:  I Lind
Journal:  Sex Transm Dis       Date:  1984 Oct-Dec       Impact factor: 2.830

10.  Novel method for detection of beta-lactamases by using a chromogenic cephalosporin substrate.

Authors:  C H O'Callaghan; A Morris; S M Kirby; A H Shingler
Journal:  Antimicrob Agents Chemother       Date:  1972-04       Impact factor: 5.191

View more
  6 in total

Review 1.  Treatment of sexually transmitted bacterial diseases in pregnant women.

Authors:  G G Donders
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

2.  Antimicrobial susceptibility, auxotype and plasmid content of Neisseria gonorrhoeae in northern Tanzania: emergence of high level plasmid mediated tetracycline resistance.

Authors:  B West; J Changalucha; H Grosskurth; P Mayaud; R M Gabone; G Ka-Gina; D Mabey
Journal:  Genitourin Med       Date:  1995-02

3.  Auxotypes, serovars, and trends of antimicrobial resistance of Neisseria gonorrhoeae in Kigali, Rwanda (1985-93).

Authors:  J Bogaerts; E Van Dyck; B Mukantabana; J P Munyabikali; W Martinez Tello
Journal:  Sex Transm Infect       Date:  1998-06       Impact factor: 3.519

4.  Antibiotic susceptibilities, serotypes and auxotypes of Neisseria gonorrhoeae isolated in New Zealand.

Authors:  M S Brett; H G Davies; J R Blockley; H M Heffernan
Journal:  Genitourin Med       Date:  1992-10

5.  The dominance of a multiresistant strain of Neisseria gonorrhoeae among prostitutes and STD patients in The Gambia.

Authors:  C A Ison; J Pepin; N S Roope; E Demba; O Secka; C S Easmon
Journal:  Genitourin Med       Date:  1992-12

6.  Molecular Typing of Neisseria gonorrhoeae Isolates by Opa-Typing and Ribotyping in New Delhi, India.

Authors:  Pejvak Khaki; Preena Bhalla; Ahmad Mir Fayaz; Sohiela Moradi Bidhendi; Majid Esmailzadeh; Pawan Sharma
Journal:  Int J Microbiol       Date:  2009-09-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.